Published in Hospital Business Week, February 25th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Abt Associates.
Report 1: An analysis of observational data from real-world clinical practice suggests Procrit (Epoetin alfa) has a lower drug cost in the outpatient setting when treating chemotherapy-induced anemia, compared with darbepoetin alfa, another drug in the same class.
Based on the average cumulative, administered doses per patient and wholesale acquisition cost (WAC), the study showed that the calculated drug cost for darbepoetin alfa was approximately 16% more than...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week